GKIM
BHVN

GW&K Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

GW&K Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-116
Closed -$18K – 511
2022
Q3 		$18K Sell
116
-776
-87% -$115K ﹤0.01% 345
2022
Q2 		$130K Sell
892
-405,364
-100% -$51.8M ﹤0.01% 348
2022
Q1 		$48.2M Buy
406,256
+25,819
+7% +$3.22M 0.43% 92
2021
Q4 		$52.4M Buy
380,437
+302,679
+389% +$38.5M 0.44% 92
2021
Q3 		$10.8M Sell
77,758
-25,606
-25% -$3.2M 0.1% 215
2021
Q2 		$10M Sell
103,364
-2,348
-2% -$191K 0.09% 220
2021
Q1 		$7.22M Buy
105,712
+4,600
+5% +$372K 0.07% 238
2020
Q4 		$8.67M Sell
101,112
-18,228
-15% -$1.54M 0.09% 223
2020
Q3 		$7.76M Buy
119,340
+23,299
+24% +$1.53M 0.1% 223
2020
Q2 		$7.02M Sell
96,041
-35,996
-27% -$1.92M 0.1% 220
2020
Q1 		$4.49M Sell
132,037
-8,009
-6% -$366K 0.08% 223
2019
Q4 		$7.62M Sell
140,046
-6,330
-4% -$313K 0.1% 217
2019
Q3 		$6.11M Buy
146,376
+42,896
+41% +$1.81M 0.09% 222
2019
Q2 		$4.53M Sell
103,480
-1,199
-1% -$67.6K 0.07% 251
2019
Q1 		$5.39M Sell
104,679
-16,627
-14% -$718K 0.09% 218
2018
Q4 		$4.49M Buy
+121,306
New +$4.37M 0.09% 206

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

GW&K Investment Management's BHVN Position: Q4 2022 in Review

GW&K Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 116 shares — an estimated $18K sold.

GW&K Investment Management first reported a position in BHVN in Q4 2018 and held it in 16 quarters. The position peaked at $52.4M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • GW&K Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • GW&K Investment Management sold 116 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $18K.
  • GW&K Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 16 quarters.
  • GW&K Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $52.4M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on GW&K Investment Management's 13F filing for Q4 2022, filed 10 Feb 2023.